NCT04560322View on ClinicalTrials.gov

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Venetoclax

Tablet, taken by mouth

DRUG

Obinutuzumab

Intravenous infusion

DRUG

Acalabrutinib

Capsule, taken by mouth

Trial Locations (3)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04560322 - Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | Biotech Hunter | Biotech Hunter